| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant human protein (amino acids Q20-A298) was used as the immunogen for the DNA-3-methyladenine glycosylase antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
DNA-3-methyladenine glycosylase Antibody / MPG / AAG is an antibody targeting MPG, raised in Rabbit for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: MPG.
- Antibody identity: Polyclonal (rabbit origin); Rabbit IgG.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Antigen affinity purified.
- Species reactivity: Human.
- Listed applications: WB, Direct ELISA (refer to on-page specifications for application-specific guidance).
Biological background
MPG (N-methylpurine-DNA glycosylase) also known as MDG, 3-METHYLADENINE DNA GLYCOSYLASE, 3MeAde DNA GLYCOSYLASE, AAG and APNG is a protein expressed in all cell lines and tissues examined, but was found at particularly high levels in a colon adenocarcinoma cell line(HT29). The completely characterized human MPG gene was found to span 7 to 8 kb of genomic DNA and to be localized 75 kb upstream of the embryonic zeta-globin gene. To assess the contribution of Apng to the repair of several mutagenic lesions in vivo,Hang et al.(1997)biochemically analyzed cell-free extracts of tissues from mice with a targeted deletion of the Apng gene. Following treatment with DNA-methylating agents, increased persistence of 7-methylguanine (meG) was found in liver sections of APNG knockout mice in comparison with wildtype mice, demonstrating an in vivo phenotype for the APNG-null animals.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
- ELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.